Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : to record 63 billion yen provision, update Q1 results on Irish tax issue

08/01/2021 | 09:10pm EDT
FILE PHOTO: Shareholders of Takeda Pharmaceutical enter the venue of their shareholders' meeting in Osaka

(Reuters) - Takeda Pharmaceutical Co said on Monday it will record a provision of about 63 billion yen ($574.56 million) in its financial statements for the first quarter to reflect a decision by Ireland's tax appeals body relating to tax assessment received by company's unit on a break fee.

Takeda said it received "a decision by the Irish Tax Appeals Commission on July 30, 2021 to uphold the Irish Revenue Commissioners' position related to the treatment of a break fee received by Shire plc in October 2014 from AbbVie Inc,".

"First Quarter FY2021 reported IRFS-based financial results will be updated to reflect the impact of the decision with no impact on core and underlying financial results," it said, adding that it will refile the revised information by Aug. 6.

Japan's biggest drugmaker said it plans to challenge this outcome through all available legal means including appealing the decision to the Irish courts.

The company is not revising its forecast for the full fiscal year 2021 and will update the outlook at appropriate timing by taking this decision as well as other factors into consideration.

Shire Plc, which Takeda acquired in 2019, received a tax assessment from the Irish Revenue Commissioners to tax a break fee the company received from AbbVie Inc for terminating its offer to acquire Shire. Takeda had appealed this assessment in 2020.

($1 = 109.6500 yen)

(Reporting by Aakriti Bhalla in Bengaluru; Editing by Kim Coghill)


ę Reuters 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/16TAKEDA PHARMACEUTICAL : Continues to Advance Growth Strategy with Sale Of Non-Co..
PU
09/16TAKEDA PHARMACEUTICAL : EXKIVITY (mobocertinib) Approved by U.S. FDA as the Firs..
AQ
09/16THERMO FISHER SCIENTIFIC : FDA Approves Tissue-Based NGS Companion Diagnostic fo..
AQ
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : Exkivity Wins FDA Approval for Treatment of Lung Cancer ..
MT
09/15TAKEDA PHARMACEUTICAL : EXKIVITY™ (mobocertinib) Approved by U.S. FDA as t..
BU
09/15Food and Drug Administration Approves Takeda’s EXKIVITYÖ (Mobocertinib) for t..
CI
09/13Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
RE
09/13TAKEDA PHARMACEUTICAL : Novavax Statement on Takeda Agreement to Provide 150 Mil..
AQ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 947 M 30 947 M
Net income 2022 253 B 2 315 M 2 315 M
Net Debt 2022 3 472 B 31 731 M 31 731 M
P/E ratio 2022 23,8x
Yield 2022 4,72%
Capitalization 5 996 B 54 771 M 54 792 M
EV / Sales 2022 2,80x
EV / Sales 2023 2,66x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 813,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 27,1%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED1.54%54 566
JOHNSON & JOHNSON4.09%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.19.23%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY37.19%208 604